IMforte Trial: Applying the Results in Practice

In this segment, the panel examines how newer studies assessing combination maintenance approaches may refine future treatment algorithms. Trials exploring maintenance with chemotherapy or targeted agents alongside immunotherapy have shown early signals of activity, suggesting that extended modulation of the tumor microenvironment could enhance durability of response.

However, panelists caution that patient selection remains critical. Only those with sufficient performance status and organ reserve should be considered for additional therapy beyond standard maintenance. They emphasize the importance of weighing incremental benefit against toxicity and cost.

While further validation is needed, these findings offer hope for expanding therapeutic options. The discussion concludes that ongoing clinical research will determine whether intensified maintenance strategies can meaningfully shift survival outcomes in extensive-stage disease.